Taking the question as asked, rather than the general version of it. Four weeks is the pharmacokinetics, not caution. With a one-week half-life you need four to five half-lives to reach steady state, so at two weeks you are dosing on top of a concentration that has not finished rising. Escalating then stacks exposure and you get the side-effect burden of the higher dose before you have seen the benefit of the current one.
Splitting this out of the general thread because the answers kept arriving in ones and twos and nobody could see the shape of it.
I titrated faster than the label because I felt fine, hit a wall at the third step, and had to come back down — which I now think was the predictable outcome rather than bad luck.
What I am trying to establish is what the trials actually did with participants who could not tolerate a step, because that is the situation I am in and the protocol summaries skip it.
Roughly, people seem to land in one of these:
- Held where they were and waited it out
- Changed one variable and kept everything else fixed
- Changed several things at once and cannot now attribute the result
- Stopped and reassessed from a clean baseline
Say which and say why — the why is the useful half.
SarahChen_PharmD said:Four weeks is the pharmacokinetics, not caution.
Agreed on the arithmetic, with one condition: holding indefinitely at a dose that is not doing anything is not patience, it is a stall with a nice name. The distinction is whether appetite has changed at all at the current step.
Ask again with the specifics and you will get a better answer than this one.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardsmatt_MKE said:I titrated faster than the label because I felt fine, hit a wall at the third step, and had to come back down — which I now think was the predictable…
This matches mine closely enough to be worth saying so. Holding longer is the underrated move. A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component tachyphylaxes while the appetite effect persists. Escalating at week two throws that adaptation away.
Adding the clinical framing, because it changes how the question reads.
PSA for titration users considering the 0.25mg starting dose: this dose is NOT intended for weight loss. It's a titration dose to let your body adjust. Don't be discouraged if you don't lose much in the first month.
The therapeutic dose for weight management starts at 1.7mg (semaglutide) or 5mg (tirzepatide). Be patient with the ramp-up.